Literature DB >> 22212157

[HIV infection].

A Potthoff1, H Rasokat, N H Brockmeyer.   

Abstract

The skin can be an indicator of decreased immunocompetence. Dermatological markers include new and extensive seborrheic eczema, psoriasis without a family history, widespread herpes zoster in young adults, oral hairy leucoplakia and mollusca in adults. In these cases an HIV test should be offered. During the last 15 years the clinical picture of HIV has changed dramatically. Almost every year new drugs with better efficacy, lower pill burden and less side effects have been approved. Life expectancy is close to normal in western countries. In spite of better treatment options, prevention is the key to stop the worldwide epidemic. Awareness campaigns have to account for the synergies between HIV and other sexually transmitted diseases. This poses a great challenge for dermatovenereology.

Entities:  

Mesh:

Year:  2012        PMID: 22212157     DOI: 10.1007/s00105-011-2195-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  20 in total

Review 1.  Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples.

Authors:  Andrew Anglemyer; George W Rutherford; Rachel C Baggaley; Matthias Egger; Nandi Siegfried
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

2.  Evaluation of the performance characteristics of 6 rapid HIV antibody tests.

Authors:  Kevin P Delaney; Bernard M Branson; Apurva Uniyal; Susan Phillips; Debra Candal; S Michele Owen; Peter R Kerndt
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 3.  Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Ryan D Cooper; Natasha Wiebe; Nathaniel Smith; Philip Keiser; Saraladevi Naicker; Marcello Tonelli
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

4.  Changes in human immunodeficiency virus testing rates among urban adolescents after introduction of routine and rapid testing.

Authors:  Tanya L Kowalczyk Mullins; Linda M Kollar; Corinne Lehmann; Jessica A Kahn
Journal:  Arch Pediatr Adolesc Med       Date:  2010-09

5.  Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Authors:  Anton L Pozniak; Joel E Gallant; Edwin DeJesus; Jose R Arribas; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

6.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Authors:  Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

7.  Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.

Authors:  Tanya Welz; Kate Childs; Fowzia Ibrahim; Mary Poulton; Chris B Taylor; Caje F Moniz; Frank A Post
Journal:  AIDS       Date:  2010-07-31       Impact factor: 4.177

Review 8.  Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.

Authors:  Emma D Deeks; Caroline M Perry
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

9.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Authors:  Jean-Michel Molina; Jaime Andrade-Villanueva; Juan Echevarria; Ploenchan Chetchotisakd; Jorge Corral; Neal David; Graeme Moyle; Marco Mancini; Lisa Percival; Rong Yang; Alexandra Thiry; Donnie McGrath
Journal:  Lancet       Date:  2008-08-23       Impact factor: 79.321

10.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.